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OBJECTIVE: To review listing recommendations made by the
Canadian Expert Drug Advisory Committee as part of the
Common Drug Review (CDR) process to gain an understanding
of how indirect comparisons between active treatments are evalu-
ated as part of reimbursement decisions. METHODS: Recom-
mendations published on CDR’s website from the point of
inception to November 2007 were reviewed by two independent
reviewers. The inclusion criterion for this evaluation was that the
reasons for the recommendation must report that no active com-
parators were used in controlled-trials despite the fact the com-
parator was available in Canada or that a meta-analysis was used
in place of a head-to-head trial. The recommendations of therapies
deemed to have used an indirect analysis were then comparedwith
reviews made of the same treatments by three other Health
Technology Assessment Agencies (HTAAs), the National Institute
for Health and Clinical Excellence in the UK, the Scottish Medi-
cines Consortium, the Institute for Quality and Efﬁciency in
Health Care in Germany. RESULTS: Of 90 recommendations
reviewed, 6 were included for full review. Of the six, ﬁve included
original indirect comparisons and one was based on a resubmis-
sion. Of the ﬁve included therapies, two utilized a pooled or
meta-analysis and three recommendations reviewed placebo or
non-controlled trials. The recommendations of the six reviews
were as follows: one general listing, three restricted listings and
two do not list recommendations. The reasons for recommenda-
tions included the results of the indirect comparisons and, also, an
interpretation of the clinical meaningfulness of the technology
and, in some cases, the resultant cost-effectiveness. Reviews,
where available, of these technologies by other HTAAs resulted in
similar reimbursement recommendations/decisions. CONCLU-
SION: The results of this evaluation suggest the use of indirect
analyses is accepted by the CDR, but is generally not the sole basis
for a listing recommendation.
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OBJECTIVE: The assignment of the Pharmaceutical Beneﬁts
Board (LFN) is to decide which pharmaceuticals should be
included in the Swedish national beneﬁts scheme. Societal cost-
effectiveness and a “need and solidarity principle” are key deci-
sion parameters. No explicit value or threshold exists. The
primary purpose is to investigate what the LFN has been willing
to pay for a QALY and relate this to other decision parameters,
in particular the perceived severity of disease. The secondary
purpose is to investigate the extent to which uncertainty in the
cost effectiveness estimate affects the LFN’s willingness to pay.
METHODS: All applications for reimbursement for new prod-
ucts from October 2002 to October 2007 were included. The
total number of applications was 205 over the 5-year period.
About half of the applications for reimbursement contained a
health economic analysis and 40% of these presented a cost-
effectiveness estimate using QALYs. The published decision as
well as the memorandum for each product was examined looking
for information on the cost per QALY, severity of disease (low,
medium or severe) as well as a measure of the uncertainty as
judged by the LFN. Decisions were classiﬁed as full reimburse-
ment, limited reimbursement or rejection. RESULTS: There is a
correlation between disease severity and willingness to pay for a
QALY. On average, the cost/QALY is €35,000. For more severe
conditions the LFN has accepted costs per QALY in the area of
€100,000. CONCLUSION: The LFN has still, after ﬁve years not
established a threshold value for the QALY. Due to a low number
of rejections it is not possible to determine a threshold. A high
degree of uncertainty in the cost-effectiveness estimate does not
seem to reduce the willingness to pay for a QALY. Instead it is
highly correlated with restrictions in the reimbursement status or
with follow up data being requested.
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OBJECTIVE: The characteristics of attractive conditional reim-
bursement settlements such as risk-sharing agreements (RSA) to
manufacturers and health care payers have previously been dis-
cussed (Sculpher et al. 2007). Mutual trust between the two
parties is a pre-requisite. Manufacturers should prefer: minimal
pre and post launch burden; clarity in the link between reim-
bursement, access, sales and retrospective/future revenue; clarity
on timing of decisions; clarity in agreements on data sharing.
Payers aim to maximise net health beneﬁt and should prefer
RSAs in which proposed research agendas are expected to most
improve knowledge of clinical effectiveness and economic value.
METHODS: We reviewed the qualities of RSAs in several Euro-
pean countries for which sufﬁcient detail had been published.
The qualities compared were: ﬁnancial burden; relationship
between reimbursement decision, access, sales and revenue;
validity of treatment effectiveness metric; clarity of decision
timing; and data-sharing agreement type. RESULTS: Four RSA
schemes were considered. The beta interferons in multiple scle-
rosis and proposed Velcade (bortezomib) in multiple myeloma
schemes in England and Wales were compared with the condi-
tional reimbursement scheme operated by The Netherlands
Health Care Insurance Board and the prospective price ﬁxing
regulations operated by the Economic Committee of Health
Products (CEP) in France. Relationships between reimbursement,
access, sales and revenues were clearest in the Velcade scheme.
The effectiveness metric used in the beta-interferons scheme was
unconventional, but reﬂective of quality of life improvements.
The 3-year reassessment timeframe of The Netherlands scheme
provided greatest decision timing clarity. The ﬁnancial burden to
manufacturers and payers of the RSAs was difﬁcult to assess.
Data-sharing agreements varied. CONCLUSION: The nature of
risk-sharing schemes in Europe is developing and highly variable.
Risk-sharing is clearly an area of policy development where
innovative proposals by manufacturers that address the concerns
of payers can lead to earlier, wider market access.
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